Fig. 4
From: Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
Potential extrinsic immune response landscapes of NOTCH4-WT and NOTCH4-MUT tumors in the TCGA cohort. A Comparison of the leukocyte fractions based on DNA methylation data between NOTCH4-WT and NOTCH4-MUT tumors. B Comparison of the lymphocyte fractions estimated by the CIBERSORT method based on RNA-sequencing data between NOTCH4-WT and NOTCH4-MUT tumors. C Comparison of the TIL fraction based on molecular estimates from processing of cancer genomics data between NOTCH4-WT and NOTCH4-MUT tumors. D Comparison of the TIL regional fractions based on estimates from processing diagnostic H&E images between NOTCH4-WT and NOTCH4-MUT tumors. E Comparison of CD8 T cells estimated by the CIBERSORT method based on RNA-sequencing data between NOTCH4-WT and NOTCH4-MUT tumors. F Comparison of the 29 immune signatures estimated by the ssGSEA method based on RNA-sequencing data between NOTCH4-WT and NOTCH4-MUT tumors. In each immune signature, the light color represents the NOTCH4-WT tumors, and the dark color represents the NOTCH4-MUT tumors. The P value is shown at the top of the graph. G Comparison of the 10 cell populations estimated by the MCP-counter method based on RNA-sequencing data between the NOTCH4-WT and NOTCH4-MUT tumors. In each cell type, the light color represents the NOTCH4-WT tumors, and the dark color represents the NOTCH4-MUT tumors. The P value is shown at the top of the graph. Statistical analysis of comparisons between two groups was conducted using the Wilcoxon test